Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surzetoclax (ABBV-453) ± Etentamig in Relapsed/Refractory Multiple Myeloma with t(11;14) or BCL2high
2025-525105-20-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label trial of surzetoclax in multiple myeloma (MM) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Dose Limiting Toxicities (DLT). Planned start Aug 2026; status: authorised.
02
Drugs
surzetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2025-525105-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525105-20-00.